| Identification | Back Directory | [Name]
[2H8]-Pantoprazole | [CAS]
934294-34-5 | [Synonyms]
[2H8]-Pantoprazole
Pantoprazole D8Q: What is
Pantoprazole D8 Q: What is the CAS Number of
Pantoprazole D8 Q: What is the storage condition of
Pantoprazole D8 Q: What are the applications of
Pantoprazole D8 | [Molecular Formula]
C16H15F2N3O4S | [MOL File]
934294-34-5.mol | [Molecular Weight]
383.37 |
| Hazard Information | Back Directory | [Uses]
Pantoprazole-d8 (BY1023-d8) is deuterium labeled Pantoprazole. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI)[1]. Pantoprazole, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142)[3][4]. | [References]
[1] Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. DOI:10.1177/1060028018797110
[2] Krupa J Patel, et al. Use of the proton pump inhibitor pantoprazole to modify the distribution and activity of doxorubicin: a potential strategy to improve the therapy of solid tumors. Clin Cancer Res. 2013 Dec 15;19(24):6766-76. DOI:10.1158/1078-0432.CCR-13-0128
[3] Huarui Zhang, et al. Advances in the discovery of exosome inhibitors in cancer. J Enzyme Inhib Med Chem. 2020 Dec;35(1):1322-1330. DOI:10.1080/14756366.2020.1754814
[4] W Beil, et al. Pantoprazole: a novel H+/K(+)-ATPase inhibitor with an improved pH stability. Eur J Pharmacol. 1992 Aug 6;218(2-3):265-71. DOI:10.1016/0014-2999(92)90178-7
[5] K Takeuchi, et al. Effects of pantoprazole, a novel H+/K+-ATPase inhibitor, on duodenal ulcerogenic and healing responses in rats: a comparative study with omeprazole and lansoprazole. J Gastroenterol Hepatol. 1999 Mar;14(3):251-7. DOI:10.1046/j.1440-1746.1999.01843.x |
|
|